Biora Therapeutics (BIOR) Stock Price, News & Analysis

Company Overview

Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.14 to $0.15
• 52-Week Range: N/A
• Volume: 16,292 shs
• Average Volume: 86,634 shs
• Market Capitalization: $660 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $23.00
• Consensus Rating: Buy

BIOR Stock Analysis - Frequently Asked Questions

How were Biora Therapeutics' earnings last quarter?

Biora Therapeutics, Inc. (NASDAQ:BIOR) announced its earnings results on Wednesday, November, 10th. The company reported ($4.60) EPS for the quarter, beating analysts' consensus estimates of ($4.70) by $0.10. The firm had revenue of $0.18 million for the quarter, compared to analysts' expectations of $11.10 million.

When did Biora Therapeutics' stock split?

Biora Therapeutics's stock reverse split on Tuesday, January 3rd 2023.The 1-25 reverse split was announced on Tuesday, January 3rd 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 3rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of Biora Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biora Therapeutics investors own include AMC Entertainment (AMC), Digital World Acquisition (DWAC), NIO (NIO), Meta Platforms (META), NVIDIA (NVDA), Bank of America (BAC) and Ford Motor (F).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 9/16/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BIOR
• CIK: 1580063
• Web: www.bioratherapeutics.com
• Phone: 833-727-2841
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Biora Therapeutics: $23.00
• High Price Target: $23.00
• Low Price Target: $23.00
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($13.04)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$124.11 million
• Net Margins: N/A
• Pretax Margin: -4,005.83%
• Return on Equity: N/A
• Return on Assets: -332.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.05
• Quick Ratio: 0.05

Sales & Book Value

• Annual Sales: $892 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($36.43) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 4,523,000
• Free Float: 2,213,000
• Market Cap: $660 thousand
• Optionable: Optionable
• Beta: 1.12